PharmaShots | Incisive News in 3 Shots

Subscribe Now

PDS Biotech

PDS Biotech Reports Updated Interim Results from the P-II Trial (VERSATILE-002) Results of PDS0101 + Keytruda for Head and Neck Cancer

PDS Biotech Reports Updated Interim Results from the P-II Trial (VERSATILE-002) Results of PDS0101 + Keytruda for Head and Neck Ca...

October 4, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer

March 31, 2023

PDS Biotech Reports P-II Clinical Trial Results of Triple Combination Therapy for Human Papillomavirus-Positive Cancers

PDS Biotech Reports P-II Clinical Trial Results of Triple Combination Therapy for Human Papillomavirus-Positive Cancers

December 30, 2022

PDS Biotech Provides Updates of PDS0101 + Keytruda (pembrolizumab) in P-II (VERSATILE-002) Trial for Advanced Head and Neck Cancer

PDS Biotech Provides Updates of PDS0101 + Keytruda (pembrolizumab) in P-II (VERSATILE-002) Trial for Advanced Head and Neck Cancer

February 3, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us